Skip to main content

Table 1 Overall population – baseline characteristics and post-index outcomes

From: Real-world clinical burden and economic assessment associated with hyperkalaemia in a large integrated healthcare system: a retrospective analysis

 

No-HK

n = 1,046,966

HK

n = 161,849

P-value

Mean age (years)

43 ± 18

60 ± 18

 < 0.0001

Age categories

  

 < 0.0001

  < 65 years

86%

56%

 

  65–74 years

8%

20%

 

  ≥ 75 years

6%

24%

 

Sex (male)

41%

51%

 < 0.0001

CCI

1.7 ± 1.4

3.5 ± 2.8

 < 0.0001a

Mean baseline sK (mmol/L)b

4.07 ± 0.39

5.38 ± 0.48

 < 0.0001

Traditional CV Risk Factors

  Hypertension

20%

63%

 < 0.0001

  Hyperlipidaemia

17%

55%

 < 0.0001

  Diabetes

7%

33%

 < 0.0001

  Smoking

13%

26%

 < 0.0001

  Renal insufficiency

0.7%

16%

 < 0.0001

  BMI, kg/m2, n = 662,888

28.4 ± 7.4

29.7 ± 8.1

 < 0.0001

  BMI categories (kg/m2)

  

 < 0.0001

    < 25

36%

29%

 

    25–29.9

31%

31%

 

    ≥ 30

33%

40%

 

  Maximum SBP

(mm Hg)

139.2 ± 71.6

162.8 ± 73.7

 < 0.0001

  EF (%)

60.9 ± 10.2

58.0 ± 12.9

 < 0.0001

Prior Diagnoses

  ASCVD

4%

21%

 < 0.0001

  CAD

1%

7%

 < 0.0001

  MI

0.6%

4%

 < 0.0001

  Stroke

0.3%

2%

 < 0.0001

  TIA

0.7%

4%

 < 0.0001

  PVD

0.1%

1%

 < 0.0001

  Heart failure

2%

20%

 < 0.0001

  Atrial fibrillation

2%

14%

 < 0.0001

Baseline Medications

  Statin

7%

39%

 < 0.0001

  Other anti-diabetic

1%

10%

 < 0.0001

  Insulin

2%

24%

 < 0.0001

  Metformin

3%

18%

 < 0.0001

  Sulfonylurea

1%

11%

 < 0.0001

  NSAID

39%

62%

 < 0.0001

  ACEi

8%

39%

 < 0.0001

  ARB

3%

16%

 < 0.0001

  Aldosterone inhibitor

0.6%

6%

 < 0.0001

  Beta-blocker

6%

32%

 < 0.0001

  Diuretic

9%

42%

 < 0.0001

  CCB

4%

22%

 < 0.0001

  Furosemide

3%

24%

 < 0.0001

  Torsemide

0.1%

1.2%

 < 0.0001

  SPS

0.04%

0.4%

 < 0.0001

  Patiromer

0%

0%

3-Year Post-Index Outcomes (n = 1,128,582)

 

n = 983,409

n = 145,173

 

  MACEc

3.2%

18.8%

 < 0.0001

  Death

2.9%

16.7%

 < 0.0001

  MI

0.05%

0.2%

 < 0.0001

  Stroke

0.2%

0.9%

 < 0.0001

  HFH

0.2%

2.8%

 < 0.0001

Multivariable Hazard Ratio (95% CI) for 3-Year MACEc

  No-HK vs HK

1.60 (1.57, 1.63), P < 0.0001

Post-Index Average Costs/Year (n = 1,208,815)

  ED

  

 < 0.0001a

    Cost ± SD

$207 ± 1,930

$552 ± 7,574

 

    Median (IQR)

11 (0, 187)

56 (0, 408)

 

  Inpatient

  

 < 0.0001a

    Cost ± SD

$1,477 ± 21,423

$10,956 ± 93,026

 

    Median (IQR)

0 (0, 740)

0 (0, 4585)

 

Age ≥ 60 years Post-Index Average Costs/Year (n = 290,972)

  ED

  

 < 0.0001a

    Cost ± SD

$222 ± 2,747

$561 ± 7,098

 

    Median (IQR)

18 (0, 219)

72 (0, 444)

 

  Inpatient

  

 < 0.0001a

    Cost ± SD

$3,765 ± 35,137

$13,844 ± 109,257

 

    Median (IQR)

0 (0, 2307)

1,277 (0, 6678)

 
  1. ACEi Angiotensin-converting enzyme inhibitor, ARB Angiotensin-II receptor blockers, ASCVD Atherosclerotic cardiovascular disease, BMI Body mass index, CAD Coronary artery disease, CCB Calcium channel blocker, CCI Charlson Comorbidity Index, CV Cardiovascular, ED Emergency department, EF Ejection fraction, HFH Heart failure hospitalization, HK Hyperkalaemia, IQR Interquartile range, MACE Major adverse CV event, MI Myocardial infarction, NSAID Nonsteroidal anti-inflammatory drug, PVD Peripheral vascular disease, SBP Systolic blood pressure, SD Standard deviation, sK Serum potassium, SPS Sodium polystyrene sulfonate, TIA transient ischaemic attack
  2. Models adjusted by baseline characteristics, risk factors, and medications
  3. aThe non-parametric Mann–Whitney rank sum test was utilized to determine P-value
  4. bTaken within ± 1 month of index date (baseline sK level)
  5. cMACE is the composite of death, MI, stroke, and HFH